group have been used in the treatment of rheumatoid arthritis with encouraging results. A number of well controlled, double-blind studies using chloroquine and hydroxychloroquine have shown that both of these drugs have anti-rheumatic properties of moderate degree.l-?
Amopyroquina esseva ben tolerate, sed un elevation asymptomatic de transaminase glutamic-oxaloacetic del sero Occurreva in quatro patientes, apparentemente in relation con le pharmaco. Altere tests del function hepatic remaneva normal.
ARIOUS SYNTHETIC antimalarial preparations of the 4-amino-quinolone
group have been used in the treatment of rheumatoid arthritis with encouraging results. A number of well controlled, double-blind studies using chloroquine and hydroxychloroquine have shown that both of these drugs have anti-rheumatic properties of moderate degree.l-?
Early reports of the use of amodiaquin (Camoquin) in rheumatoid arthritis were also encouraging; but gastrointestinal, neurologic, hepatic, and hematologic manifestations were serious enough to limit its usefulness.s-10 Similar side effects have been reported in the treatment of discoid and systemic lupus erythematosus with am~diaquin.ll-~~ Amopyroquin (Propoquin ) is a close analogue of amodiaquin ( fig. 1) . Preliminary studies in animalsl6 and man indicated good tolerance, low toxicity, and effective antimalarial properties.
We, therefore, undertook a preliminary clinical trial to determine the antirheumatic properties and the toxicity of amopyroquin in patients with rheumatoid arthritis. Classical double-blind, cross-over technics were used to compare amopyroquin with placebo.
AMOPYROQUIN (PROPOQUIN)
Pig. 1
MATERIALS AND METHODS
Fifteen adult patients with active, classical or definite rheumatoid arthritis were selected. Active disease had been present for at least 1 year, and all patients had at least five clinically active joints at the outset of the study. None had ever received antimalarial drugs in the past. Systemic steroids had not been used for at least 3 months, although intra-articular steroids were used in a few cases during the study. Single joints were injected i n three patients while on placebo, and in one patient while on amopyroquin. Patients receiving maintenance crysotherapy were acceptable if more than 1.5 Gm. had been given, and if their disease was stable and active (two cases). Gold was discontinued when the study was started. All patients were on salicylates and home physical therapy programs. These were continued. At the beginning of the study, patients were instructed in the ad lib. Methods of Analysis Table 1 Table 4 compares the first Smonth period of each group. It is to be noted that Group B (placebo) has seven cases-one dropped out at the end of the first period. Improvement occurred in all indices in patients receiving amopyroquin, but only Lansbury's articular index was significant ( p = 0.03). However, the sedimentation rate and systemic index approached statistical significance. In the placebo group, only morning stiffness and total tender joints showed improvement. These were not statistically significant.
RESULTS
Comparing Groups A and B for the first 5-month period, the latex titer fell in four of the five latex positive patients on amopyroquin, and in two of the five positive patients on placebo. When switched to amopyroquin, the remaining three patients in the latter group showed a fall in titer. The decrease in titer was of two tube dilutions or more in seven cases, and one tube dilution in two cases. Subcutaneouus nodules disappeared or were decreased in number in three patients on amopyroquin, and in one on placebo .
There was very little change in the gamma globulin values with amopyroquin, but a definite increase in serum albumin occurred. Serum albumin decreased in all except one patient while on placebo.
No appreciable weight change occurred on amopyroquin. There was a mean loss of 1/4 lb. ( -8 to +11 lb.) . On placebo, the mean weight change was minus 2% Ib. ( -15 to +10 lb.) . The x-rays revealed very little change during the 10-month period. Erosions increased slightly in two patients on placebo, and two on amopyroquin. There appeared to be slight improvement in one case while on amopyroquin.
Toxicity
Amopyroquin was not stopped in any patient because of untoward symptoms or abnormal physical findings. Symptoms suggestive of toxicity were more frequent in patients on placebo, particularly anorexia, abdominal distress, headaches, and edema. Nausea, vomiting, or diarrhea were not seen while on amopyroquin. Skin rash and pruritus likewise were not associated with the active preparation. Transient blurred vision was noted in two patients on placebo and one on amopyroqdn. These patients and several others had slit lamp examinations after the study, and no abnormalities were encountered.
A transient lowering of the leukocyte count occurred in three patients on amopyroquin to levels of 4000-4500 cells/cu. mm. There was essentially no change in values far blood urea nitrogen w complete urinalyses. 
